Literature DB >> 19959033

Secondary malignancies across the age spectrum.

Andrea K Ng1, Lisa B Kenney, Ethel S Gilbert, Lois B Travis.   

Abstract

Development of a second malignancy is one of the most serious late effects in survivors of both childhood and adult-onset cancers. Patterns of second malignancy risk across the age spectrum can differ in terms of the types of second malignancies observed, magnitude of the risks, the latency period, associated risk factors, and modifying influences. Potential explanations for the varying risk patterns by age include differences in susceptibility of individual tissue/organ to carcinogenesis based on stage of development and level of tissue maturity, microenvironment, attained age, and lifestyle factors. A thorough understanding of these differences is essential when considering treatment modifications in newly diagnosed cancer patients who are aimed at reducing the risk of second malignancy and other late effects without compromising cure. Moreover, an understanding of the variations in second cancer risk according to age at treatment is important in customizing patient follow-up.

Entities:  

Mesh:

Year:  2010        PMID: 19959033      PMCID: PMC3857758          DOI: 10.1016/j.semradonc.2009.09.002

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  117 in total

1.  Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours.

Authors:  J Pedersen-Bjergaard; G Daugaard; S W Hansen; P Philip; S O Larsen; M Rørth
Journal:  Lancet       Date:  1991-08-10       Impact factor: 79.321

2.  Second neoplasms after acute lymphoblastic leukemia in childhood.

Authors:  J P Neglia; A T Meadows; L L Robison; T H Kim; W A Newton; F B Ruymann; H N Sather; G D Hammond
Journal:  N Engl J Med       Date:  1991-11-07       Impact factor: 91.245

3.  Bone sarcomas linked to radiotherapy and chemotherapy in children.

Authors:  M A Tucker; G J D'Angio; J D Boice; L C Strong; F P Li; M Stovall; B J Stone; D M Green; F Lombardi; W Newton
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

4.  Cancer in the contralateral breast after radiotherapy for breast cancer.

Authors:  J D Boice; E B Harvey; M Blettner; M Stovall; J T Flannery
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

5.  Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.

Authors:  C H Pui; R C Ribeiro; M L Hancock; G K Rivera; W E Evans; S C Raimondi; D R Head; F G Behm; M H Mahmoud; J T Sandlund
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

6.  Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group.

Authors:  M A Tucker; P H Jones; J D Boice; L L Robison; B J Stone; M Stovall; R D Jenkin; J H Lubin; E S Baum; S E Siegel
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

7.  Prediction of familial predisposition to retinoblastoma.

Authors:  W K Cavenee; A L Murphree; M M Shull; W F Benedict; R S Sparkes; E Kock; M Nordenskjold
Journal:  N Engl J Med       Date:  1986-05-08       Impact factor: 91.245

8.  Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases.

Authors:  C H Pui; M V Relling; G K Rivera; M L Hancock; S C Raimondi; H E Heslop; V M Santana; R C Ribeiro; J T Sandlund; H H Mahmoud
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

9.  Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Lisa B Kenney; Yutaka Yasui; Peter D Inskip; Sue Hammond; Joseph P Neglia; Ann C Mertens; Anna T Meadows; Debra Friedman; Leslie L Robison; Lisa Diller
Journal:  Ann Intern Med       Date:  2004-10-19       Impact factor: 51.598

10.  Risk of contralateral breast cancer in Denmark 1943-80.

Authors:  H H Storm; O M Jensen
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

View more
  42 in total

1.  Effect of organ size and position on out-of-field dose distributions during radiation therapy.

Authors:  Sarah B Scarboro; Marilyn Stovall; Allen White; Susan A Smith; Derek Yaldo; Stephen F Kry; Rebecca M Howell
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

2.  Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT.

Authors:  Jan Kriz; Max Spickermann; Philipp Lehrich; Heinz Schmidberger; Gabriele Reinartz; Hans Eich; Uwe Haverkamp
Journal:  Strahlenther Onkol       Date:  2015-04-16       Impact factor: 3.621

3.  Secondary Malignancies Following Treatment for Hodgkin's Lymphoma in Childhood and Adolescence.

Authors:  Wolfgang Dörffel; Marianne Riepenhausenl; Heike Lüders; Jürgen Brämswig; Günther Schellong
Journal:  Dtsch Arztebl Int       Date:  2015-05-01       Impact factor: 5.594

4.  The antioxidant tempol reduces carcinogenesis and enhances survival in mice when administered after nonlethal total body radiation.

Authors:  James B Mitchell; Miriam R Anver; Anastasia L Sowers; Philip S Rosenberg; Maria Figueroa; Angela Thetford; Murali C Krishna; Paul S Albert; John A Cook
Journal:  Cancer Res       Date:  2012-07-17       Impact factor: 12.701

5.  Testicular germ cell tumor: Short and long-term side effects of treatment among survivors.

Authors:  Thierry Gil; Spyridon Sideris; Fouad Aoun; Roland van Velthoven; Nicolas Sirtaine; Marianne Paesmans; Lieveke Ameye; Ahmad Awada; Daniel Devriendt; Alexandre Peltier
Journal:  Mol Clin Oncol       Date:  2016-07-14

6.  Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use.

Authors:  Kassondra S Grzankowski; J Brian Szender; Chandra L Spring-Robinson; Shashikant B Lele; Kunle O Odunsi; Peter J Frederick
Journal:  Int J Gynecol Cancer       Date:  2016-10       Impact factor: 3.437

7.  Unusual presentation of a rare cancer: histiocytic sarcoma in the brain 16 years after treatment for acute lymphoblastic leukemia.

Authors:  Sreelatha Chalasani; Mark R Hennick; William G Hocking; Gene R Shaw; Benjamin Lawler
Journal:  Clin Med Res       Date:  2012-09-20

8.  Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.

Authors:  Joanne Ngeow; Kim Stanuch; Jessica L Mester; Jill S Barnholtz-Sloan; Charis Eng
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

9.  Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin's disease.

Authors:  J Koeck; Y Abo-Madyan; H T Eich; F Stieler; J Fleckenstein; J Kriz; R-P Mueller; F Wenz; F Lohr
Journal:  Strahlenther Onkol       Date:  2012-06-29       Impact factor: 3.621

Review 10.  Risk and survival outcomes of radiation-induced CNS tumors.

Authors:  Jessica W Lee; A Gabriella Wernicke
Journal:  J Neurooncol       Date:  2016-05-21       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.